

PAC 2014 - Global Partnering for Open Innovation Program

2014. 11. 18 ~ 11.19, Ritz-Carlton SEOUL, Grand Ballroom A3F

Day 1: Nov 18 (Tuesday)		HOST: Jung-Ryun Ahn (GSK)
8:30 (30')	Registration	
9:00 (10')	Opening remarks: <ul style="list-style-type: none"> • Kyung-Ho Lee, KPMA/Chairman • Jin-Ho Kim, KRPIA/Chairman 	
9:10 (10')	Welcome Address: <ul style="list-style-type: none"> • Minister or Vice Minister of MOHW (TBD) • Chunjin Kim, Chair of National Assembly Health & Welfare Committee 	
9:20 (50')	Keynote Speech: Chair: Woolck Jang , Handok Inc. <ul style="list-style-type: none"> • ByoungJun Bae, MOHW/ Director General, Bureau of Health Industry (TBD) Government Policy for Pharma Industry: Vision & Goal of 5-year Comprehensive Plan • Robert J. Hariri, Celgene/Chairman, Founder and CSO for Cellular Therapeutics New Paradigm of Pharma R&D for Efficiency and Success 	
10:10 (60')	Session R-1: R&D Innovation Through Partnership in Asia Chair: Yil-Seob Lee , GSK <ul style="list-style-type: none"> • Duncan McKay, GSK/VP, EMAP R&D; GSK External R&D Innovation in Emerging Market and AsiaPacific • Jia-hua Wang, Novartis Oncology/Director, Asia Pacific Region Medical Affairs Baek Min Seong, Novartis/ Head, Strategic partnership Korea/Asia Lead in BD&L R&D Opportunity & Partnership in Asia <ul style="list-style-type: none"> • Q&A 	
11:10 (20')	Coffee Break	
11:30 (60')	Session M-1: Novel Drug Discovery for Orphan Diseases Chair: Joong-Gon, Kim , Seoul National University <ul style="list-style-type: none"> • Jei-Wook Chae, Bioneer Inc./ Idiopathic Pulmonary Fibrosis • YoungKyu Cho, Handok Inc / IL-1RA hyFC Development for Rare Diseases • Wan Namkung, Yonsei University Identification of Small-Molecule Correctors for ΔF508-CFTR Using High-throughput Screening • Q&A 	
12:30 (60')	Lunch Break	

<p>13:30 (60')</p>	<p>Session R-2: R&D Collaboration for Innovation Chair: Su Nam, Yuhan</p> <ul style="list-style-type: none"> • Kenichi Nishida, Daiichi-Sankyo/Senior Director, External Science Planning, R&D planning Early Phase Research Collaboration Activities Featuring TaNeDS Drug Discovery Program in Daiichi Sankyo • Frank Degner, Boehringer Ingelheim/ Head, Clinical Development & Medical Affairs Implications of Globalized Clinical Drug Development for Local and Regional Clinical Operations • Q&A
<p>14:30 (60')</p>	<p>Session M-2: Essence of KDDF(Korea Drug Development Fund) Projects Chair: Dong-Ho Lee, Ulsan University</p> <ul style="list-style-type: none"> • Kyeong- Cheon Jung, Dinona Inc./ JL1 epitope of CD43, a Novel Therapeutic Target in Acute Leukemia • Sanghee, Yoo, Hanall Biopharma./ HL161: a Novel Anti-FcRn Antibody as a New Therapeutic Option For Autoimmune Diseases • Yoon-Won Kim, ImmuneMed Inc./ Development of Newly Defined Antiviral Drug That Selectively Acts On the Viral Infected Cells • Q&A
<p>15:30 (20')</p>	<p>Coffee Break</p>
<p>15:50 (70')</p>	<p>Session R-3: Open Innovation Strategy for Biopharmaceuticals Chair: James Jun, KT&G</p> <ul style="list-style-type: none"> • Yariv Hefez, Merck Serono/Vice president, Business Development, Licensing & Alliance Management, Biosimilar division The Role of Asia In a Global Biosimilar Business Strategy and Partnership Opportunities In Asia • Yuan-Hua Ding, Pfizer/ Executive Director, Head, External R&D Innovation - AP Alliances to Drive Biomedical Innovation (Subtitle: Overview of Pfizer R&D, Partner Strategy and Asia Initiatives) • Elena Rizova, Janssen/ VP, J&J Innovation center at Shanghai Johnson & Johnson as Catalyzer of innovation • Q&A
<p>17:00 (60')</p>	<p>Session M-3: Empowered biologics Chair: Young-Woo Park, KRIBB</p> <ul style="list-style-type: none"> • Jin-San Yoo, PharmAbcine, Inc./CEO and President Clinical Development of Tanibirumab and Its Next Generation of Bispecific Antibody • Soon-Jae Park, Alteogen Inc./CEO Herceptin ADC by New ConjugationTechnology or Long Acting FVIIa by Use of NexP Fusion Technology • Yong-Joo Kim, LegoChem Biosciences Inc /CEO Toward Well-defined ADC • Q&A
<p>18:00</p>	<p>Welcome Reception (Invitation Only)</p>

Day 2: Nov 19 (Wednesday)		HOST: Myungha Park (BI)
7:30 (60')	Breakfast meeting with gov't policy makers (Invitation Only) Organized by KPMA & KRPIA	
8:30 (30')	Registration	
9:00 (30')	Keynote Speech: (TBD) Chair: Seong-Choon Choe , Boryung Pharmaceutical <ul style="list-style-type: none"> • Si Young Song, Yonsei Univ. Health System “ (TBD)” 	
9:30 (40')	Session M-4 : Essence of National Oncoventure(NOV) projects Chair: In-Chul, Kim , National Oncoventure/ <ul style="list-style-type: none"> • Jung Yong, Kim , NOV/ Introduction of TGF-beta R1 Inhibitor Program of Medpacto Inc. • Young-Whan Park, NOV/ Introduction of Vascular Disrupting Agent Program of Chong Kun Dang Pharm • Q&A 	
10:10 (60')	Session R- 4: R&D Alliance for Innovation Chair: Joy H.J. Chung , KHIDI/Executive Consultant <ul style="list-style-type: none"> • Takato Noumi, Sanofi/Director, External Science & Partnering Japan Sanofi's Strategy for Open Innovation and Partnering • Hiroya Muranishi, Takeda/ Senior Director, Research Alliance, Pharmaceutical Research Division Takeda's Alliance Approach for Therapeutic Research Innovation • Q&A 	
11:10 (50')	Session M-5: First-in-class NCEs Chair: Bong Yong Lee , Daewoong Pharmaceutical Co. Ltd./ Head of Research <ul style="list-style-type: none"> • Dong Hoon Jin, Ulsan University E3 Ubiquitin Ligase-dependent Pathway As a Novel Therapeutic Strategy • Yong H Roh, Obetat Biopharma/President OBT1026: Novel Peptide Therapy for Severe Obesity • Wheeseong Lee, KT&G Life Sciences NAD Modulator for Mitochondrial Disorders • Q&A 	
12:00 (5')	Closing KPMA Sangsuk Lee, KRPIA/CEO	